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Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for
Parkinson’s Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of
413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine
months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based
techniques (within patients’ score changemethod and sensitivity- and specificity-basedmethod by receiver operating characteristic
analysis) and distribution-based approaches (effect size calculations) were utilized to determine themagnitude ofminimal clinically
important difference. Results. According to our results, any improvements larger than −3.44 points or worsening larger than 2.07
points can represent clinically important changes for the patients.These thresholds have the effect size of 0.21 and−0.21, respectively.
Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients.
Studies using the PDSS-2 as outcome measure should utilize the threshold of −3.44 points for detecting improvement or the
threshold of 2.07 points for observing worsening.
The present scientific contribution is also dedicated to the 650th anniversary of the foundation of the University of Pe´cs,
Hungary
1. Introduction
The nonmotor symptoms of Parkinson’s disease (PD) have
been increasingly recognized as major burden of quality of
life [1, 2]. Sleep-related problems are one of the most frequent
and troublesome nonmotor aspects of PD. Sleep-related
problems are certainly multidimensional.The recently devel-
oped Parkinson’s Disease Sleep Scale 2nd version (PDSS-
2) was designed to be simultaneously able to capture the
multidimensional aspects of sleep-related problems and any
changes in sleep quality [3]. It consists of 15 items evaluating
three domains (motor symptoms at night, PD symptoms at
night, and disturbed sleep) [3]. Symptoms on each domain
can be scored in the range of 0–20 points, higher scores
representing more nighttime sleep-related problems. The
sum of the three domains gives the total score of PDSS-2 with
the maximum value of 60 points. PDSS has been translated
and validated into several languages [4, 5] and has good
clinical validity [6]. The threshold indicating sleep problems
is 11 points for the Hungarian version of PDSS-2 [7].
Even though the PDSS-2 has been utilized in several phar-
macological [8–12] and neurosurgical [13] studies to identify
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any improvement in nocturnal sleep quality, the magnitude
of change required to represent a clinically meaningful
improvement has not been evaluated yet.
One of the major issues in recent biomedical research
is the evaluation of clinical meaning of changes on patients’
reported outcomes (PROs). As some changes may be sta-
tistically significant but clinically irrelevant, statistical sig-
nificance does not necessarily imply clinical importance:
interventions with small effect size, for example, may have no
clinical importance for the patients or clinicians.
To overcome this issue, the concern of minimal clinically
important difference (MCID) was introduced in late 1980s.
Jaeschke et al. defined the MCID as “the smallest difference
in score in the domain of interest which patients perceive
as beneficial and which would mandate. . .a change in the
patient’s management” [14]. In other words, MCID is the
smallest change in an outcome measure that a patient would
identify as important. Therefore, MCID offers a threshold
abovewhich outcome is experienced as relevant by the patient
avoiding the problem of mere statistical significance.
Evaluation of MCIDs for different outcome measures not
only is important because of clinical decision-making and the
labeling claims of medical products but also is required for
study design as it is essential for calculating the sample sizes
required for different trials and surveys.
However, there are some important issues with theMCID
thresholds. First, thresholds for detecting minimal clinically
meaningful improvement and worsening may be asymmet-
ric.Therefore, different threshold values may exist for detect-
ing improvement and deterioration on the same outcome
measure [15].
A more troublesome concern is the methodology- and
sample-dependent nature of MCID. At the moment numer-
ous different approaches are available for MCID calculations
(e.g., anchor-based and distribution-based techniques). For
example, application of different methods even on the same
sample can result in different MCID values [15, 16]. On
the contrary, the usage of the same outcome measures and
methods for MCID calculation on different study popula-
tion can also yield different MCID thresholds [15, 17]. To
overcome these problems, an article summarizing the recom-
mendations on methods for evaluating MCID was recently
published [18]. According to its proposals, the estimation of
MICD for a specific outcome measure should be based
on multiple approaches. Because the PRO measures should
correlate with the appropriate clinical anchor used for deter-
mining MCID, the value of correlation coefficient should be
at least 0.3 between them.
The aim of the present study was to determine the
estimates of MCID for Parkinson’s Disease Sleep Scale 2nd
version (PDSS-2) in a longitudinal observational setup. Our
protocol fully complied with the recommendations for deter-
mining MCIDs [18] and simultaneously multiple techniques
were assessed for the calculations.
2. Materials and Methods
2.1. Patients. In this prospective study 413 consecutive
patients fulfilling the UK Brain Bank criteria for PD were
enrolled [19] at Department of Neurology, University of Pe´cs,
Hungary, between 2013 and 2015.The patients were examined
by neurologists specialized in movement disorders. Each
subject gave written informed consent in accordance with
the ethical approval of Regional and Institutional Ethical
Committee (3617.316-24987/KK41).
2.2. Obtained Rating Scales. Besides PDSS-2 sociodemo-
graphic and PD-related data were obtained and the patients
were screened for dementia by the means of Montreal
Cognitive Assessment andMattis Dementia Rating Scale [20]
at baseline. Patients with atypical parkinsonism or dementia
(receiving ≤125 points on Mattis scale and/or fulfilling the
criteria of DSM-5 for major neurocognitive disorder in PD
[21, 22]) were excluded from the study. Severity of Parkinson’s
disease was assessed by the Hungarian validated version of
Movement Disorders Society-Sponsored Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) [23, 24], the Hoehn-
Yahr Scale (HYS) [25], and the Schwab-England Scale (SES)
[26]. Implying the recommendations of theMovementDisor-
ders Society Task Force, the original HYS was obtained and
treated as ordinal values [27]. Baseline characteristics of the
study population are demonstrated in Table 1.
Patients were reexamined 9 months (275 ± 21 days) later
after receiving standard clinical care. After completing the
PDSS-2 questionnaire, the patients were asked to describe
if their sleep quality was either “very much better,” “much
better,” “a little better,” “the same,” “a little worse,” “much
worse,” or “very much worse” since the last visit. These
answers were identical with the Hungarian validated version
of Patient-Rated Global Impression of Improvement (PGI-I)
items adjusted for sleep problems.
2.3. Anchor-BasedMethods to DetermineMCID. Theanchor-
based approaches utilize either patient-based or clinician-
based external indicator to assign subjects into several group-
ings reflecting no change, small negative changes, large nega-
tive changes, small positive changes, or large positive changes.
Two different types of anchor-based approaches were applied
to determine CIDs. These types of methods require an
independent standard or anchor that is simultaneously inter-
pretable by itself, clinically relevant, and correlated with the
instrument being evaluated [28, 29]. For this study, the above-
mentioned PGI-I items served as the anchors for calculating
the MCID estimates for PDSS-2.
2.3.1. Within-Patients Score Change Method. This approach
defines MCID as the change between the PRO scores of a
group of patients selected according to their answer to a
global assessment scale (anchor). Therefore, in this study we
calculated the mean change on the PDSS-2 dimensions and
the total score for those subjects who indicated “no change” at
follow-up or for thosewho indicated “a little worse” or “a little
better” change.
2.3.2. Sensitivity- and Specificity-Based Approach. This sec-
ond anchor-based method is useful in calculating the thresh-
old that allows for the best discrimination between groups of
patients. For example, the score that produces the greatest
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Table 1: The demographic and disease-specific characteristics of the study population (𝑛 = 413) at baseline examination.
Mean or number
of patients Standard deviation Median Percentile 25 Percentile 75
Age 64.83 9.20 65.00 59.00 72.00
Sex 285M/128F
Education (years) 11.9 3.4 12.0 11.0 16.0
Disease duration 9.91 5.99 9.00 5.00 13.00
HYS (number of patients at stage 1/2/3/4/5) 68/125/170/35/15
Patients on levodopa (baseline) 215 (52.1%)
Patients on levodopa (follow-up) 265 (64.2%)
Levodopa dosage (baseline, in LED, mg) 585.4 472.1 520.0 200.0 812.5
Levodopa dosage (follow-up, in LED, mg) 735.3 490.4 620.0 350.0 912.5
Patients on dopamine-agonists (baseline) 165 (39.9%)
Patients on dopamine-agonists (follow-up) 324 (78.5%)
Dopamine agonist dosage (baseline, in LED,
mg) 215.6 244.9 160.0 .0 320.0
Dopamine agonist dosage (follow-up, in LED,
mg) 323.2 234.4 324.0 98.5 420.0
Patients on benzodiazepines (both baseline and
follow-up) 44 (10.7%)
Schwab-England 74.2 13.9 80.0 70.0 90.0
MDS-UPDRS nMEDL 14.8 6.5 14.0 10.0 19.0
MDS-UPDRS MEDL 17.0 8.3 16.0 10.0 23.0
MDS-UPDRS ME 40.3 14.8 39.0 29.0 48.0
MDS-UPDRS MC 5.2 3.6 5.0 2.0 7.0
MDS-UPDRS total score 77.2 25.8 74.0 58.0 91.0
PDSS-2 motor symptoms domain 4.7 3.9 5.0 2.0 7.0
PDSS-2 PD symptoms domain 3.6 3.3 4.0 1.0 5.0
PDSS-2 disturbed sleep domain 7.3 4.1 7.0 4.0 10.0
PDSS-2 total score 15.6 9.6 16.0 8.0 21.0
HYS: Hoehn-Yahr Stages; LED: levodopa equivalent dosage; MDS-UPDRS: Movement Disorders Society Sponsored Version of Unified Parkinson’s Disease
Rating Scale; MDS-UPDRS MC: Motor Complications (Part 4 of MDS-UPDRS); MDS-UPDRS ME: Motor Examination (Part 3 of MDS-UPDRS); MDS-
UPDRSMEDL: Motor Experiences of Daily Living (Part 2 of MDS-UPDRS); MDS-UPDRS nMEDL: Non-Motor Experiences of Daily Living (Part 1 of MDS-
UPDRS).
sensitivity and specificity for discriminating patients with
minimal change from patients without any change can be
considered as the MCID. Generally sensitivity is the pro-
portion of subjects with a positive test out of the group of
subjects who were truly positive. Likewise, specificity is the
proportion of subjects with a negative test out of the group
of subjects who were truly negative. Used in conjunction
with MCID estimations, sensitivity is the proportion of the
patients who report a change on the external criterion (i.e.,
PGI-I) and whose PRO score (e.g., PDSS-2) change exceeds
the thresholdMCID value. Similarly, specificity is the propor-
tion of subjects who do not report a change on the external
criterion (anchor) and whose PRO score changes are below
the thresholdMCIDvalue.A sensitivity of 100% indicates that
all true positives are identified, whereas a specificity of 100%
indicates that all the true negatives are identified.
In our study, we applied receiver operating characteristic
(ROC) curve technique to find the most suitable MCID
values. Because the recommendations for desirable MCID
sensitivity and specificity levels have yet to be determined
[18], we followed the method described by Hauser et al.
[15, 17]. Assuming that false-positive and false-negative iden-
tifications are equally unwanted, we determined the cutoff
value with the most optimal balance between sensitivity and
specificity. The optimal cutoff points to distinguish changes
on PDSS-2 between subjects rated as minimally worsened or
minimally improved and subjects rated as unchanged on the
PGI-I score were estimated as the point on the ROC curve
closest to the point of (0, 1). It was calculated as theminimum
value of the square root of (1 − sensitivity)2 + (1− secificity)2.
For the most optimal cutoff values the positive (LR+) and
negative (LR−) likelihood-ratios were also determined using
the following formulas:
LR+ = True positive rate
False positive rate
=
Sensitivity
(1 − Specificity)
,
LR− =
False negative rate
True negative rate
=
(1 − Sensitivity)
Specificity
.
(1)
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2.4. Distribution-Based Method to Determine MCID. The
distribution-based methods compare the changes in PRO
scores to some measure of variability. However, the distri-
bution-based estimates provide no direct information about
the MCID. They are simply a way of describing the observed
differences in a standardized metric [18].
Effect size is generally a measure of exactly how strong
the relationship that was being examined is. Common effect
sizes are mean differences, correlation coefficients, regression
coefficients, odds ratios, and hazard ratios. The value of the
effect size represents the number of standard deviations (SDs)
bywhich the scores have changed frombaseline to the follow-
up. By convention, an effect size of 0.2 is considered as small,
0.5 as moderate, and 0.8 as large [18]. Used in conjunction
with anchor-basedmethods, effect size ascertains the respon-
siveness of the external criterion. With regard to MCID, for
example, the change in scores corresponding to small effect
size should estimate the MCID value [18, 29].
2.5. Statistical Analysis. All statistical analyses were carried
out using IBM SPSS software package (version 21, SPSS
Inc., Chicago, USA). We calculated Spearmen’s correlation
coefficients to assess the relationship between the PGI-I and
the changes in PDSS-2 scores. Comparison of baseline and
follow-up scores was performed by paired 𝑡-tests. Statistical
significance level was set to 5%. Because the SPSS Suite
did not have built-in functions for calculating positive and
negative predictive values, we utilized the syntax available on
the IBM website (http://www-01.ibm.com/support/docview
.wss?uid=swg21483380, assessed on Jan 15, 2013).
3. Results
During the observational period the levodopa dose in LED
increased from 585.4 ± 472.1mg to 735.3 ± 490.4mg and the
dopamine-agonist dose (measured in LED) increased from
215.6 ± 244.9mg to 323.2 ± 234.4mg, whereas the number of
patients on dopamine-agonist therapy increased from 165 to
324 (Table 1).
3.1. Anchor-Based MCID Estimation. The Spearman correla-
tion coefficient assessing the correlation between the PGI-
I and the change in PDSS-2 was 0.364 (𝑝 < 0.001). As a
correlation coefficient higher than 0.3 between the anchor
and the PRO is required for detecting MCID [18], our study
setting can be considered as a suitable dataset for detecting
MCID for PDSS-2.
3.1.1. Within-Patients Score Change Method. Because we
aimed to determine only the magnitude of minimal clini-
cally important difference, only the data for those judged
minimally improved (𝑛 = 142), unchanged (𝑛 = 126), and
minimally worse (𝑛 = 154) are presented in Table 2.
Mean changes (±SD) for PDSS-2 for subjects rated min-
imally improved, unchanged, or minimally worse on PGI-
I scale are demonstrated in Table 2. The mean change for
patients rating the same sleep quality was −0.54 (±3.24),
whereas for minimal improvement it was −3.44 (±6.40) and
for minimal worsening it was 2.07 (±7.72) points on the total
score of PDSS-2 (Table 2).
3.1.2. Sensitivity- and Specificity-Based Approach. Subse-
quently we performed ROC analysis between the changes in
the total score of PDSS-2 compared and the PGI-I as state
variable. The most optimal cutoff value discriminating the
minimal improvement was ≤−3 points on the total score
of PDSS-2, whereas the best cutoff to identify the minimal
worsening was ≥2 points (Table 3).
3.2. Effect Size Method. The estimates calculated by anchor-
based methods for detecting minimal clinically meaningful
improvement and worsening represent the effect size of 0.21
and −0.21, respectively.
Because both anchor-based and distribution-based calcu-
lations gave similar results, we could estimate that the thresh-
old representing minimal clinically important difference for
improvement was −3.44 points and for worsening it was
+2.07 points.
4. Discussion
Following the recommendations of Revicki et al. [18], our
aim was to evaluate the magnitude of minimal clinically
important difference on PDSS-2. By the utilization of the
combination of both anchor- and distribution-based meth-
ods, we were able to estimate the MCID thresholds for the
total score of PDSS-2 congruently. Based on our results, the
magnitude of MCID is asymmetric for improvement and
worsening. According to our results, any improvement larger
than−3.44 points and anyworsening larger than +2.07 points
can represent clinically important changes for the patients.
This asymmetry is probably due to the asymmetric percep-
tion of sleep quality. According to our data relatively larger
improvements are required to be judged by the patients as
positive improvement, whereas a relatively smaller worsening
can elicit the perception of worsening.
One of the limitations of our studymay be that we utilized
only patient-derived anchors for assessing MICD and our
data is not based on the objective (e.g., polysomnographic or
actigraphic) findings. Because sleep quality is very subjective,
in our opinion the severity of sleep problems can only reliably
be described by the patients. There is no objective physical
or instrumental examination which could reliably measure
the sleep quality of the patients. Not even the sleep labs
can describe all dimensions of the sleep. Polysomnography
(PSG), for example, can objectively detect the presence and
measure the severity of PMLS in an artificial setup, but it is
still unable to capture several other aspects of sleep quality
[30, 31]. Although the PDSS was validated against PSG [30,
31], not even the original (English) version of PDSS-2 was
validated against any sleep lab tests [3]. This was the reason
why we applied a patient-derived (and not a clinician-based)
anchor to assess the MICD. Because similar approach was
utilized for pain outcomes [32], our method is acceptable for
detecting MICD for PDSS-2.
Since its publication in 2011 [3], a growing number of
studies utilized the PDSS-2 to evaluate changes in sleep
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Table 3: Best cutoff values discriminatingminimal clinically important differences for PDSS-2 determined by receiver operating characteristic
analysis.
ROC curve cutoff Sensitivity Specificity +LR −LR AUC Significance
PGI-I
A little better <−3 54.00 51.40 1.11 0.89 0.523 0.046
The same NA
A little worse ≥2 50.98 65.42 1.47 0.75 0.613 0.023
AUC: area under the curve; +LR: positive likelihood-ratio; −LR: negative likelihood-ratio; PDSS-2: Parkinson’s Disease Sleep Scale 2nd version; PGI-I: Patient-
Rated Global Impression of Improvement; ROC: receiver operating characteristic analysis.
problems of PD patients. However, in the lack of MICD value
for PDSS-2, these studies could demonstrate only statistical
significance and not clinically meaningful difference.
The first larger study aimed to investigate the effects of
rotigotine on nocturnal sleep quality [33]. This was the first
study where early morning motor function and nocturnal
sleep-disturbances served as the coprimary endpoints. In
this double-blind study, the mean PDSS-2 total score had
decreased by −5.9 points with rotigotine and by −1.9 points
with placebo. Because the difference between the active and
placebo arm (−4.0) is larger than ourMCIDvalue (−3.56), the
observed difference can be considered as clinically meaning-
ful.
Zibetti et al. demonstrated that 2–4 months’ long levod-
opa/carbidopa intestinal gel (LCIG) treatment can improve
the nighttime sleep quality in PD measured by PDSS-2
(improvement from 34.0 points to 20.9 points) [10]. Similar
efficacy was observed by Kova´cs et al. [12]. They observed 7-
point improvement (from 25 points to 18 points) on PDSS-2
total score after 6-month long LCIG treatment [12].
Recently, Deli et al. demonstrated the beneficial effects
of bilateral subthalamic deep brain stimulation on the sleep
quality in PD. In that study the total score of PDSS-2
decreased from 24 (median, IQR: 17–32) to 10 (median, IQR:
7–18) points (𝑝 < 0.001) in the population of 25 advanced PD
patients [13].Meanwhile, the number of patients having clini-
cally troublesome sleep problems also decreased from 13 to 3.
Based on ourMCID estimations, all of these reported changes
are also clinically meaningful.
5. Conclusions
Minimal clinically important differences are the smallest
change of scores that are subjectively meaningful to patients.
The results of our study estimate the minimum magnitude
of change that should be sought when studies are designed
using the PDSS-2 to evaluate the change over time in the sleep
quality in PD. Studies using the PDSS-2 as outcome measure
should utilize the threshold of −3.44 points for detecting
improvement or the threshold of +2.07 points for observing
worsening.
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